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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established, potentially curative treatment modality for malignant and non-malignant hematological diseases. Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic HSCT and limits its wider use.
Traditionally, GVHD has been divided into two forms, acute and chronic, based on the time of its onset. Acute GVHD has been defined as disease occurring in the first 100 days following transplant while chronic GVHD occurs after day 100. This arbitrary distinction based on the time of onset fails to reflect the different pathophysiologic mechanisms and clinical manifestations of acute and chronic GVHD, though. Acute GVHD can occur after day 100 in patients that received a nonmyeloablative conditioning regimen or donor lymphocyte infusions. Vice versa, GVHD with typical clinical features of chronic GVHD can develop well before day 100 and concurrent with acute GVHD. Therefore, the National Institutes of Health consensus development project has defined new criteria for the diagnosis, staging, and response assessment of chronic GVHD. 1, 2 Only few effective therapies are currently available for the treatment of both forms of GVHD. The established immunosuppressive agents are mostly non-specific and unfortunately associated with severe side effects, in particular the susceptibility to life-threatening infections.
Therefore, novel more selective agents are urgently needed.
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GVHD is an immune-mediated disease that results from a complex interaction between donor and recipient adaptive immunity. Donor-derived CD4 + and CD8 + T lymphocytes have classically been considered to be the main effector cells mediating GVHD pathogenesis. In fact, removal of T cells from transplant inocula almost completely prevents GVHD from developing, however, at the price of increased incidences of graft rejection and disease recurrences. In recent years, basic and clinical research has provided a more detailed mechanistic understanding of the molecules and cell types involved in the biology of the graft-versus-host reaction.
Since acute GVHD is thought to be mediated mainly by donor T cells preventive and Little is known about the involvement of B cells in the pathogenesis of acute GVHD.
In mice, B cell depletion results in a decreased incidence of acute GVHD. were refractory to multiple immunosuppressants with rituximab. 54 Three patients who 1 3 received rituximab showed a complete response of their acute GVHD. Results from recent studies indicate that B cell depletion might also be effective for the prevention of acute GVHD. Rituximab administered as part of a myeloablative or nonmyeloablative conditioning regimen or given shortly before or after transplant results in lower than expected rates of GVHD. 55-59 However, contrary to these studies posttransplant administration of rituximab did not reduce the incidence of GVHD in a trial of allogeneic stem cell transplantation in patients with high risk relapse of aggressive B cell NHL. 60 It therefore seems that the timing of rituximab administration is a relevant factor and that early B cell depletion is crucial. Importantly, rituximab administered before or shortly after transplantation appears safe and does not interfere with engraftment. 61 Not unexpectedly, B cell recovery is delayed, though.
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Consistent with a role of donor B cells in acute GVHD, high numbers of B lymphocytes in the apheresis product correlate with an increased incidence of acute GVHD and increased treatment-related mortality. 63 Thus, activation of donor B cells contained in the stem cell graft by cognate interaction with alloantigens could result in activation and expansion of alloreactive donor T cells.
On the contrary, even though recipient APCs are essential for the initiation of acute GVHD, host B cells can also have a protective effect. Paradoxically, B cell-deficient mice experience more severe acute GVHD than wild-type mice. 64 In this experimental model IL-10 production by recipient B cells is responsible for the suppression of acute GVHD. This is interesting since IL-10 was identified as a critical modulator of acute GVHD. [65] [66] [67] [68] In humans a high content of B cell progenitors in the stem cell graft is associated with a significantly lower rate of acute GVHD. 
B cells and chronic GVHD
Chronic GVHD is a major cause of morbidity and mortality in long-term survivors of allogeneic hematopoietic stem cell transplantation. Up to 70% of patients experience chronic GVHD. It may develop continuously from acute GVHD, recur after resolution of acute GVHD, or it may occur de novo. HLA disparity, source of progenitor cells, graft composition, donor and patient age and sex, and previous acute GVHD have been identified as the main risk factors predicting the development chronic GVHD.
The use of stem cells from peripheral blood is associated with an increased rate of chronic GVHD. 70 Chronic GVHD affects a wide range of organs. Among the most commonly affected organs are the skin, liver, gut, lung, and mucous membranes.
Chronic GVHD has features resembling autoimmune disorders such as scleroderma, frequently be found and they correlate with the occurrence of chronic GVHD. 82, 83 These antibodies are derived from donor B cells and are the result of a coordinated response of B and T cells. 84, 85 Weekly administration of rituximab for one month starting two months after transplantation prevents the development of anti-H-Y antibodies and seems to protect against the development of chronic GVHD.
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Whether the occurrence of antibodies in GVHD represents a bystander effect caused by polyclonal B cell activation remains unknown. In fact, to date a direct involvement of autoantibodies in GVHD pathology has not been conclusively demonstrated.
Transfer of autoantibodies from mice with GVHD to normal mice failed to cause autoimmune pathology. 87 On the other hand, stimulatory antibodies to the platelet derived growth factor receptor which can be found in patients with chronic GVHD or systemic sclerosis but not in patients without GVHD are able to induce an increased production of collagen from human fibroblasts in vitro. 75 In light of these findings, Chronic GVHD is associated with a perturbed B cell homeostasis. 88 Like patients with autoimmune disease patients who develop chronic GVHD have a relative reduction in naïve B cells and relatively higher numbers of activated memory-type CD27 + B cells. 89 Elevated levels of BAFF have been correlated with the development and severity of chronic GVHD. [89] [90] [91] High levels of BAFF in the presence of lower numbers of naïve B cells might foster the survival of activated alloreactive and autoreactive B cells resulting in immune pathology. 89 Interestingly, patients with chronic GVHD had a faster initial reconstitution of the B cell population. 73 In line with the notion that alloreactive donor B cells drive the GVH-reaction, a higher content of B cells in the stem cell graft was identified as a risk factor for the occurrence of chronic GVHD. 92, 93 For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
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The incidental clinical observation that treatment of immune thrombocytopenia in a patient with chronic GVHD with rituximab led to improvement of some manifestations of chronic GVHD such as xerophtalmia and enabled discontinuation of immunosuppression raised the question whether the depletion of B cells could be used to treat chronic GVHD. 94 Subsequently, the effectiveness of rituximab for the treatment of chronic GVHD was confirmed by several case series and small clinical trials. [95] [96] [97] [98] [99] [100] [101] [102] GVHD such as immune-mediated thrombocytopenia, and pure red cell aplasia have also been reported to respond to rituximab treatment. 94, 104 Addition of rituximab to prednisone may enable successful steroid tapering. B cell depletion may therefore be a promising approach for the treatment of chronic GVHD particularly steroidrefractory skin disease. The finding that treatment with rituximab starting two months after non-myeloablative conditioning reduced alloreactive B cell responses and was associated with a low incidence of chronic GVHD indicates that B cell depletion could furthermore serve as a GVHD prophylaxis after allogeneic stem cell transplantation. with chronic myelogeneous leukemia. 107 To the same end, alloantibodies to H-Y minor histocompatibility antigens are associated with disease remission. 82 
B cells and the graft-versus-tumor effect
acute GVHD. Besides antibodies against T lymphocytes ATG contains antibodies reactive with several B cell-specific antigens such as CD19 and CD20 and the plasma cell marker CD138 that can induce B cell and plasma cell apoptosis. 110, 111 Surprisingly, a recent study in mice showed that inhibitors of HMG-CoA-reductase, also known as statins, can inhibit acute GVHD. 112 Small studies in humans seem to confirm the potential of statins as a GVHD-modifying drug in acute 113 For For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
